189 related articles for article (PubMed ID: 34720020)
1. Tryptophan 2,3-dioxygenase, a novel therapeutic target for Parkinson's disease.
Boros FA; Vécsei L
Expert Opin Ther Targets; 2021 Oct; 25(10):877-888. PubMed ID: 34720020
[TBL] [Abstract][Full Text] [Related]
2. Tryptophan-2,3-dioxygenase (TDO) inhibition ameliorates neurodegeneration by modulation of kynurenine pathway metabolites.
Breda C; Sathyasaikumar KV; Sograte Idrissi S; Notarangelo FM; Estranero JG; Moore GG; Green EW; Kyriacou CP; Schwarcz R; Giorgini F
Proc Natl Acad Sci U S A; 2016 May; 113(19):5435-40. PubMed ID: 27114543
[TBL] [Abstract][Full Text] [Related]
3. Expression of tryptophan 2,3-dioxygenase and production of kynurenine pathway metabolites in triple transgenic mice and human Alzheimer's disease brain.
Wu W; Nicolazzo JA; Wen L; Chung R; Stankovic R; Bao SS; Lim CK; Brew BJ; Cullen KM; Guillemin GJ
PLoS One; 2013; 8(4):e59749. PubMed ID: 23630570
[TBL] [Abstract][Full Text] [Related]
4. Identification of paeoniflorin from Paeonia lactiflora pall. As an inhibitor of tryptophan 2,3-dioxygenase and assessment of its pharmacological effects on depressive mice.
Liang X; Su T; Wu P; Dai Y; Chen Y; Wang Q; Cao C; Chen F; Wang Q; Wang S
J Ethnopharmacol; 2023 Dec; 317():116714. PubMed ID: 37315645
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological validation of TDO as a target for Parkinson's disease.
Perez-Pardo P; Grobben Y; Willemsen-Seegers N; Hartog M; Tutone M; Muller M; Adolfs Y; Pasterkamp RJ; Vu-Pham D; van Doornmalen AM; van Cauter F; de Wit J; Gerard Sterrenburg J; Uitdehaag JCM; de Man J; Buijsman RC; Zaman GJR; Kraneveld AD
FEBS J; 2021 Jul; 288(14):4311-4331. PubMed ID: 33471408
[TBL] [Abstract][Full Text] [Related]
6. Tryptophan: A Rheostat of Cancer Immune Escape Mediated by Immunosuppressive Enzymes IDO1 and TDO.
Kim M; Tomek P
Front Immunol; 2021; 12():636081. PubMed ID: 33708223
[TBL] [Abstract][Full Text] [Related]
7. Genetic alterations affecting the genes encoding the enzymes of the kynurenine pathway and their association with human diseases.
Boros FA; Bohár Z; Vécsei L
Mutat Res Rev Mutat Res; 2018; 776():32-45. PubMed ID: 29807576
[TBL] [Abstract][Full Text] [Related]
8. Tryptophan 2,3-dioxygenase and indoleamine 2,3-dioxygenase 1 make separate, tissue-specific contributions to basal and inflammation-induced kynurenine pathway metabolism in mice.
Larkin PB; Sathyasaikumar KV; Notarangelo FM; Funakoshi H; Nakamura T; Schwarcz R; Muchowski PJ
Biochim Biophys Acta; 2016 Nov; 1860(11 Pt A):2345-2354. PubMed ID: 27392942
[TBL] [Abstract][Full Text] [Related]
9. Targeting key dioxygenases in tryptophan-kynurenine metabolism for immunomodulation and cancer chemotherapy.
Austin CJ; Rendina LM
Drug Discov Today; 2015 May; 20(5):609-17. PubMed ID: 25478733
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of stress-induced hepatic tryptophan 2,3-dioxygenase exhibits antidepressant activity in an animal model of depressive behaviour.
Gibney SM; Fagan EM; Waldron AM; O'Byrne J; Connor TJ; Harkin A
Int J Neuropsychopharmacol; 2014 Jun; 17(6):917-28. PubMed ID: 24472498
[TBL] [Abstract][Full Text] [Related]
11. IDO and TDO as a potential therapeutic target in different types of depression.
Qin Y; Wang N; Zhang X; Han X; Zhai X; Lu Y
Metab Brain Dis; 2018 Dec; 33(6):1787-1800. PubMed ID: 30014175
[TBL] [Abstract][Full Text] [Related]
12. Synthesis of novel tryptanthrin derivatives as dual inhibitors of indoleamine 2,3-dioxygenase 1 and tryptophan 2,3-dioxygenase.
Li Y; Zhang S; Wang R; Cui M; Liu W; Yang Q; Kuang C
Bioorg Med Chem Lett; 2020 Jun; 30(11):127159. PubMed ID: 32247733
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of STAT-mediated cytokine responses to chemically-induced colitis prevents inflammation-associated neurobehavioral impairments.
Sin R; Sotogaku N; Ohnishi YN; Shuto T; Kuroiwa M; Kawahara Y; Sugiyama K; Murakami Y; Kanai M; Funakoshi H; Chakraborti A; Bibb JA; Nishi A
Brain Behav Immun; 2023 Nov; 114():173-186. PubMed ID: 37625556
[TBL] [Abstract][Full Text] [Related]
14. Substrate stereo-specificity in tryptophan dioxygenase and indoleamine 2,3-dioxygenase.
Capece L; Arrar M; Roitberg AE; Yeh SR; Marti MA; Estrin DA
Proteins; 2010 Nov; 78(14):2961-72. PubMed ID: 20715188
[TBL] [Abstract][Full Text] [Related]
15. The effects of a novel and selective inhibitor of tryptophan 2,3-dioxygenase on tryptophan and serotonin metabolism in the rat.
Salter M; Hazelwood R; Pogson CI; Iyer R; Madge DJ
Biochem Pharmacol; 1995 May; 49(10):1435-42. PubMed ID: 7539265
[TBL] [Abstract][Full Text] [Related]
16. Role of tryptophan metabolism in cancers and therapeutic implications.
Liu XH; Zhai XY
Biochimie; 2021 Mar; 182():131-139. PubMed ID: 33460767
[TBL] [Abstract][Full Text] [Related]
17. Tryptophan kynurenine metabolism as a common mediator of genetic and environmental impacts in major depressive disorder: the serotonin hypothesis revisited 40 years later.
Oxenkrug GF
Isr J Psychiatry Relat Sci; 2010; 47(1):56-63. PubMed ID: 20686200
[TBL] [Abstract][Full Text] [Related]
18. Can kynurenine pathway be considered as a next-generation therapeutic target for Parkinson's disease? An update information.
Qin W; Shi Y; Chen W; Jia X; Asakawa T
Biosci Trends; 2022 Sep; 16(4):249-256. PubMed ID: 36002303
[TBL] [Abstract][Full Text] [Related]
19. Antimicrobial and immunoregulatory properties of human tryptophan 2,3-dioxygenase.
Schmidt SK; Müller A; Heseler K; Woite C; Spekker K; MacKenzie CR; Däubener W
Eur J Immunol; 2009 Oct; 39(10):2755-64. PubMed ID: 19637229
[TBL] [Abstract][Full Text] [Related]
20. Tryptophan 2,3-dioxygenase in tumor cells is associated with resistance to immunotherapy in renal cell carcinoma.
Sumitomo M; Takahara K; Zennami K; Nagakawa T; Maeda Y; Shiogama K; Yamamoto Y; Muto Y; Nukaya T; Takenaka M; Fukaya K; Ichino M; Sasaki H; Saito K; Shiroki R
Cancer Sci; 2021 Mar; 112(3):1038-1047. PubMed ID: 33410234
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
